.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,946,235

« Back to Dashboard

Claims for Patent: 8,946,235

Title:2-(2,4,5-substituted-anilino) pyrimidine compounds
Abstract: The present invention relates to certain 2-(2,4,5-substituted-anilino)pyrimidine compounds and pharmaceutically acceptable salts thereof which may be useful in the treatment or prevention of a disease or medical condition mediated through certain mutated forms of epidermal growth factor receptor (for example the L858R activating mutant, the Exon19 deletion activating mutant and the T790M resistance mutant). Such compounds and salts thereof may be useful in the treatment or prevention of a number of different cancers. The invention also relates to pharmaceutical compositions comprising said compounds and salts thereof, especially useful polymorphic forms of these compounds and salts, intermediates useful in the manufacture of said compounds and to methods of treatment of diseases mediated by various different forms of EGFR using such compounds and salts thereof.
Inventor(s): Butterworth; Sam (Cheshire, GB), Finlay; Maurice Raymond Verschoyle (Cheshire, GB), Ward; Richard Andrew (Cheshire, GB), Redfearn; Heather Marie (Cheshire, GB)
Assignee: AstraZeneca AB (Sodertalje, SE)
Application Number:13/557,871
Patent Claims: 1. A compound, or a pharmaceutically acceptable salt thereof, wherein the compound is N-(2-{2-dimethylaminoethyl-methylamino}-4-methoxy-5-{[4-(1-methylindol-3-- yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide.

2. A pharmaceutical composition, which comprises the compound according to claim 1, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically-acceptable diluent or carrier.

3. A method for treating lung cancer in a warm-blooded animal in need of such treatment, which comprises administering to said animal an effective amount of the compound of claim 1, or a pharmaceutically acceptable salt thereof.

4. A compound, wherein the compound is N-(2-{2-dimethylaminoethyl-methylamino}-4-methoxy-5-{[4-(1-methylindol-3-- yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide.

5. A pharmaceutical composition, which comprises the compound according to claim 4, in association with a pharmaceutically-acceptable diluent or carrier.

6. A method for treating lung cancer in a warm-blooded animal in need of such treatment, which comprises administering to said animal an effective amount of the compound of claim 4.

7. A mesylate salt of N-(2-{2-dimethylaminoethyl-methylamino}-4-methoxy-5-{[4-(1-methylindol-3-- yppyrimidin-2-yl]amino}phenyl)prop-2-enamide.

8. A pharmaceutical composition, which comprises the mesylate salt according to claim 7, in association with a pharmaceutically-acceptable diluent or carrier.

9. A method for treating lung cancer in a warm-blooded animal in need of such treatment, which comprises administering to said animal an effective amount of the mesylate salt of claim 7.

10. The method of claim 3, wherein the lung cancer is non-small cell lung cancer.

11. The method of claim 6, wherein the lung cancer is non-small cell lung cancer.

12. The method of claim 9, wherein the lung cancer is non-small cell lung cancer.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc